|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (ARMO). Lilly's tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 per share in cash, expired as scheduled on Thursday, June 21, 2018. As of the expiration of the tender offer, 27,542,054 shares of ARMO common stock were validly tendered and not properly withdrawn, representing approximately 90.6 percent of the shares of ARMO common stock outstanding, and have been accepted for payment under the terms of the tender offer.
NEW YORK , June 5, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. (ARMO) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of ARMO ...
NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , May 18, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
BALA CYNWYD, PA / ACCESSWIRE / May 16, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO" ...
The high-profile departure would be the latest in a string of exits of top investors in recent years from one of Silicon Valley's oldest and most successful venture firms.
WeissLaw is investigating whether ARMO's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $75.00 per share, or $25.00 above the offer price. Moreover, the deal is a strategic transaction that will expand LLY's drug portfolio and provide LLY a foothold in the very lucrative cancer immunotherapy industry.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
BALA CYNWYD, PA / ACCESSWIRE / May 10, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO'' ...
The latest earnings release ARMO BioSciences Inc’s (NASDAQ:ARMO) announced in December 2017 indicated company earnings became less negative compared to the previous year’s level – great news for investors BelowRead More...
Legendary venture capital firm Kleiner Perkins Caufield & Byers bought into Redwood City's ARMO BioSciences Inc. in December 2012 when Series A shares sold for $1. It stuck with the company into a January IPO at $17 and now with a $50-per-share buyout by Eli Lilly & Co.
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ARMO BioSciences, Inc. stockholders concerning the proposed acquisition of the company by Eli Lilly and Company .
The deal between the two companies will have Eli Lilly acquiring ARMO Biosciences Inc for $50 per share. This represents a roughly 68% premium to ARMO stock’s closing price on Wednesday. The agreement between ARMO Biosciences Inc and Eli Lilly will have the latter making a tender offer of $50 per share for ARMO stock.
NEW YORK , May 10, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against ARMO BioSciences, Inc. (NASDAQ: ARMO) and its board of directors for breach of fiduciary duty concerning ...
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal.
Lilly's offer of $50 per share in cash represents a premium of 68 percent to Armo's Wednesday close. Armo's shares were trading close to the offer price at $49.73, while Lilly's shares rose 1.2 percent to $80.22. The deal comes just four months after Armo went public and would give Lilly access to the smaller drug developer's lead candidate, pegilodecakin.
The following statement is being issued by Levi & Korsinsky, LLP:
SAN DIEGO , May 10, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ARMO BioSciences, Inc. (NASDAQ: ARMO) breached their ...
INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and ARMO BioSciences, Inc. (ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.